Fiduciary Alliance LLC raised its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 1,002.7% in the first quarter, HoldingsChannel.com reports. The firm owned 35,210 shares of the exchange traded fund’s stock after buying an additional 32,017 shares during the period. Fiduciary Alliance LLC’s holdings in SPDR S&P Biotech ETF were worth $4,804,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the business. Dynamic Wealth Strategies LLC grew its holdings in shares of SPDR S&P Biotech ETF by 3.8% during the fourth quarter. Dynamic Wealth Strategies LLC now owns 2,201 shares of the exchange traded fund’s stock valued at $268,000 after buying an additional 80 shares during the last quarter. Capital Investment Advisory Services LLC raised its holdings in shares of SPDR S&P Biotech ETF by 4.0% in the 4th quarter. Capital Investment Advisory Services LLC now owns 2,123 shares of the exchange traded fund’s stock worth $259,000 after acquiring an additional 81 shares during the last quarter. Commerce Bank raised its holdings in shares of SPDR S&P Biotech ETF by 2.8% in the 4th quarter. Commerce Bank now owns 3,260 shares of the exchange traded fund’s stock worth $397,000 after acquiring an additional 90 shares during the last quarter. Compass Ion Advisors LLC lifted its position in SPDR S&P Biotech ETF by 2.6% in the 4th quarter. Compass Ion Advisors LLC now owns 3,886 shares of the exchange traded fund’s stock valued at $474,000 after acquiring an additional 97 shares in the last quarter. Finally, Moors & Cabot Inc. lifted its position in SPDR S&P Biotech ETF by 3.8% in the 3rd quarter. Moors & Cabot Inc. now owns 2,717 shares of the exchange traded fund’s stock valued at $272,000 after acquiring an additional 100 shares in the last quarter.
SPDR S&P Biotech ETF Stock Performance
XBI stock opened at $149.71 on Thursday. The business has a 50-day simple moving average of $134.55 and a two-hundred day simple moving average of $128.31. The company has a market capitalization of $9.55 billion, a P/E ratio of 11.47 and a beta of 0.85. SPDR S&P Biotech ETF has a 52-week low of $82.04 and a 52-week high of $151.78.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
